Results 201 to 210 of about 27,357 (215)

Optimization and Characterization of Aqueous Micellar Formulations for Ocular Delivery of an Antifungal Drug, Posaconazole.

Current pharmaceutical design, 2020
BACKGROUND Topical therapy is preferred for the management of ocular fungal infections due to its superiorities which include overcoming potential systemic systemic side effect risk of drugs, and targeting of drugs to the site of disease.
M. Durgun, E. Kahraman, S. Güngör, Y. Özsoy   +3 more
semanticscholar   +1 more source

Posaconazole Cocrystal with Superior Solubility and Dissolution Behavior

Crystal Growth & Design, 2019
This work reports the first cocrystal of the basic drug posaconazole (PSZ). PSZ is poorly water-soluble and has low and erratic bioavailability based on its large positive food effect and high solu...
G. Kuminek, Katie L. Cavanagh, M. D. da Piedade, N. Rodríguez-Hornedo   +3 more
semanticscholar   +1 more source

Initial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed-release tablet and intravenous posaconazole.

Pediatric Transplantation, 2020
Posaconazole is a broad-spectrum antifungal used for prophylaxis and treatment of invasive fungal diseases. There are limited data on the optimal dosing, safety, and efficacy of the DRT and IV formulations in immunocompromised pediatric and adolescent ...
Valeria Bernardo, A. Miles, A. Fernandez, R. Liverman, Ashley Tippett, I. Yildirim   +5 more
semanticscholar   +1 more source

Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial

The Lancet, 2021
J. Maertens, G. Rahav, Dong‐Gun Lee, A. Ponce-de-León, Isabel Cristina Ramírez Sánchez, N. Klimko, A. Sonet, S. Haider, J. Vélez, I. Raad, L. Koh, M. Karthaus, Jianying Zhou, R. Ben-Ami, M. Motyl, Seongah Han, Anjana Grandhi, H. Waskin   +17 more
semanticscholar   +1 more source

Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn).

Journal of Antimicrobial Chemotherapy, 2019
BACKGROUND First-line antifungal treatment for invasive mucormycosis (IM) consists of liposomal amphotericin B. Salvage treatment options are limited and often based on posaconazole oral suspension.
J. Salmanton-García, D. Seidel, P. Koehler, Sibylle C. Mellinghoff, R. Herbrecht, N. Klimko, Z. Ráčil, I. Falces-Romero, P. Ingram, Miguel-Ángel Benítez-Peñuela, J. Rodríguez, G. Desoubeaux, A. Barać, C. García-Vidal, M. Hoenigl, S. Mehta, M. Cheng, G. Klyasova, W. Heinz, N. Iqbal, R. Krause, H. Ostermann, O. Penack, E. Schalk, D. Sheppard, B. Willinger, H. Wisplinghoff, J. Vehreschild, O. Cornely, M. Vehreschild, R. A. Khedr, Alberto Arencibia-Núñez, M. Avilés-Robles, I. Banke, A. Basher, Keertilaxmi Benachinamardi, H. Bertz, A. Chakrabarti, Ľ. Drgoňa, J. García-Martínez, J. García-Rodríguez, Sandra Gräber, G. Härter, M. Klein, M. Kouba, Dong‐Gun Lee, Y. Le Govic, Fabian Leo, J. Maertens, G. Maschmeyer, L. Meintker, X. Mo, Lena K. Müller, Nicolas Müller, J. Nel, J. Novak, Atul K. Patel, F. Pfäfflin, J. Pozo-Laderas, P. Puerta-Alcalde, A. Rodríguez-Guardado, R. Schroers, V. Shekar, S. Shenoi, G. Silling, D. Vinh, Salomón Waizel-Haiat, Mandy Yap Yee Yee, P. Prakash, P. Žák   +69 more
semanticscholar   +1 more source

Posaconazole

Reactions Weekly, 2017
  +8 more sources

Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug–drug interaction predictions using a PBPK approach

Cancer Chemotherapy and Pharmacology, 2021
Sumit Bhatnagar, Dwaipayan Mukherjee, A. Salem, D. Miles, R. Menon, J. Gibbs   +5 more
semanticscholar   +1 more source

Posaconazole

Reactions Weekly, 2023
openaire   +2 more sources

Posaconazole

Reactions Weekly, 2022
  +5 more sources

Posaconazole

Reactions Weekly, 2018
  +5 more sources